Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
上海药明生物技术有限公司 Wuxi Biologics
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
WuXi Biologics Reports Remarkable 2022 Annual Results
2023-03-22 20:09
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
2023-01-05 08:30
WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List
2022-12-16 08:44
WuXi Biologics Provides Corporate Updates
2022-10-27 22:13
WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China
2022-10-26 12:30
WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities
2022-10-24 08:30
WuXi Biologics Receives "Best CDMO Award of the Year"
2022-10-14 09:00
WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody
2022-10-12 09:00
WuXi Biologics Co., Ltd. Removed from Unverified List
2022-10-10 07:55
WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts
2022-09-29 10:41
WuXi Biologics' Drug Substance and Drug Product Facilities Again Approved by U.S. FDA and EMA
2022-09-20 10:48
WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey
2022-08-31 20:00
WuXi Biologics Reports Strong 2022 Interim Results
2022-08-17 21:32
WuXi Biologics Again Selected as Constituent of FTSE4Good Index Series
2022-08-17 10:12
WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapore
2022-07-19 18:03
WuXi Vaccines Received First GMP Certificate of QC Potency Lab from Ireland Health Products Regulatory Authority
2022-07-12 16:00
WuXi XDC and AbTis Sign Memorandum of Understanding for Development and Manufacturing of Antibody Drug Conjugates
2022-07-08 09:27
WuXi Biologics Extends Capabilities to Include Development and cGMP Manufacturing for Microbial-Derived Products
2022-07-05 08:30
WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes
2022-06-06 08:30
WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustainability
2022-04-28 08:30
1
2
3
4
5
8